Skip to main content
Figure 3 | BMC Pulmonary Medicine

Figure 3

From: A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Figure 3

FEV 1 from 0 to 4 h and at 24 h on a) Day 1 and at b) Week 12 (PPS). Data are LSM ± standard error; FEV1 = forced expiratory volume in 1 second; PPS = per-protocol set. A. p < 0.001 at all time points from 0–4 h; p = not significant at 24 h. B. p = not significant at all time points.

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us